REVELATION BIOSCIENCES, INC.
جودة البيانات: 83%
KWD 1.17
▼
KWD 0.06
(-4.88%)
القيمة السوقية: 4.58 M
السعر
KWD 1.23
القيمة السوقية
4.58 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Negative free cash flow of -8.29 M
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-120.23%
أقل من متوسط القطاع (-53.53%)
ROIC-96.66%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
N/A
Current Ratio6.92
Interest CoverageN/A
التقييم
PE (TTM)
-0.51
أعلى من متوسط القطاع (-1.48)
P/B Ratio0.42
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1366 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1366 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -0.5 | -1.5 |
| P/B | 0.4 | 1.6 |
| ROE % | -120.2 | -53.5 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
2 محللين
Buy
الحالي
KWD 1.17
المستهدف
KWD 19.25
KWD 16.00
KWD 19.25
KWD 22.50
التوقعات
مكرر الربحية المستقبلي
-0.36
ربحية السهم المستقبلية
-KWD 3.30
الإيرادات المقدّرة
0.0
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 3.30
-KWD 4.24 – -KWD 2.35
|
0.0 | 2 |
| FY2026 |
-KWD 4.16
-KWD 5.69 – -KWD 2.62
|
0.0 | 2 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 1.04
-KWD 1.46 – -KWD 0.61
|
0.0 | 2 |
| 2026 Q1 |
-KWD 1.15
-KWD 1.55 – -KWD 0.75
|
0.0 | 2 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 3.66 | -KWD 1.65 | +54.9% |
| Q32025 | -KWD 5.34 | -KWD 7.08 | -32.6% |
| Q22025 | -KWD 24.60 | -KWD 28.04 | -14.0% |
| Q12025 | -KWD 82.56 | -KWD 25.32 | +69.3% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -8.91 M |
| ROE | -120.23% | ROA | -97.68% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -8.29 M |
| ROIC | -96.66% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 6.92 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 10.98 M | Tangible Book Value | 11.00 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.51 | Forward P/E | N/A |
| P/B Ratio | 0.42 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -181.13% | ||
| Market Cap | 4.58 M | Enterprise Value | -8.13 M |
| Per Share | |||
| EPS (Diluted TTM) | -23.95 | Revenue / Share | N/A |
| FCF / Share | -2.23 | OCF / Share | -2.22 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 92.99% |
| SBC-Adj. FCF | -8.55 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -8.91 M | -15.04 M | -120,254.0 | -10.83 M | -2.13 M |
| EPS (Diluted) | -23.95 | -87.68 | -0.53 | -20.09 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -9.07 M | -7.98 M | -8.66 M | -10.86 M | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 4.06 M | 3.55 M | 4.15 M | 5.38 M | — |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | — | 41,759.0 |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 11.58 M | 6.62 M | 12.21 M | 5.50 M | 48.39 M |
| Total Liabilities | 2.72 M | 1.91 M | 5.56 M | 4.45 M | 8.40 M |
| Shareholders' Equity | 8.86 M | 4.71 M | 6.65 M | 1.05 M | -7.82 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 10.70 M | 6.50 M | 11.99 M | 5.25 M | 78,532.0 |
| Current Assets | 10.81 M | 6.57 M | 12.15 M | 5.41 M | 83,366.0 |
| Current Liabilities | 2.00 M | 1.91 M | 5.56 M | 4.45 M | 5.49 M |
{"event":"ticker_viewed","properties":{"ticker":"REVB","listing_kind":"stock","pathname":"/stocks/revb","exchange":"Nasdaq","country":"US"}}